Black women with breast cancer often deal with an uncomfortable and at times painful side effect known as neuropathy, but a ...

Clin Ovarian Cancer. 2009;2(1):44-47.

The most important take-home information from the INTERLACE trial is that in some people with cervical cancer that are ...

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...

Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in ...

The selection and schedule of treatment should depend on patient preference and toxicity potential, according to Azka Ali, MD.

MCCLEAN, VA, UNITED STATES, January 14, 2025 /EINPresswire / -- Perthera, a leader in AI-driven precision oncology, announces a groundbreaking adva ...

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

Vascarta has obtained the exclusive rights to a novel method of creating more effective cancer therapies with fewer side effects applying new and unique linker chemistry developed by the City College ...

Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with ...

Oncolytics Biotech® Inc. , a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany's medical regulatory body, the Paul-Ehrlich-Institute (PEI), has ...

胰腺癌是一种发病率持续攀升的侵袭性全身性疾病，预计到2030年将成为癌症相关死亡的第二大常见原因。胰腺癌的预后普遍较差，相关诊疗指南中标准诊疗路径和标准治疗方案的更新一直为广大临床医生所关注。近期，美国国家综合癌症网络（NCCN）更新了胰腺癌2025 ...